A Phase 4, Open-label Study of KRYSTEXXA® (Pegloticase) Co-administered With Methotrexate (MTX) in Patients With Uncontrolled Gout (FORWARD OL) (FORWARD OL)

• ClinicalTrials.gov Identifier: NCT04762498
• Recruitment Status: Recruiting
• First Posted: February 21, 2021
• Last Update Posted: December 13, 2022
• Sponsor: Horizon Therapeutics Ireland DAC
• Information provided by (Responsible Party): Horizon Pharma Ireland, Ltd., Dublin Ireland ( Horizon Therapeutics Ireland DAC )

Study Description

Brief Summary:

This trial is to assess efficacy, safety, blood levels and bodily effects of up to 2 dose levels of intravenous (IV) pegloticase (KRYSTEXXA) infusions at every 4 week intervals (Q4 Weeks) for up to 6 months (Day 1 to 24 weeks with an optional 24 - 48 weeks treatment duration) when given in combination with weekly oral doses of methotrexate (MTX). The goal is to identify an appropriate dose to be administered every 4 weeks to be used for future clinical trials for patients with chronic gout that does not adequately respond to conventional therapy.

Condition or disease	Intervention/treatment	Phase
Uncontrolled Gout; Chronic Gout	Biological: Pegloticase and Methotrexate (MTX)	Phase 4

Detailed Description:

The primary objective is to choose a dose for further investigation by assessing the effect of up to 2 dose levels of pegloticase administered IV Q4 weeks, co-administered with weekly doses of oral MTX, as measured by the sustained normalization of serum uric acid (sUA) to < 6 mg/dL for at least 80% of the time during Month 6 and the duration of sUA to < 6 mg/dL over 24 week treatment period in adult participants with chronic gout refractory to conventional therapy.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 40 participants
• Allocation: Non-Randomized
• Intervention Model: Sequential Assignment
• Intervention Model Description: Screening period up to 35 days, followed by 4-week methotrexate (MTX) tolerability run-in. Treatment consists of pegloticase IV Q4 Wks dose for a total of 6 infusions (24 Weeks) with co-administered weekly oral MTX. Optional extension treatment (24-48 weeks) will be available for 6 more infusions (total of 12). Study will consist of Cohort 1: 16 mg pegloticase, co-administered with weekly doses of oral MTX; and, potential Cohort 2: 24 to 32 mg pegloticase, co-administered with weekly doses of oral MTX and/or potential infusion duration reduction to 60 min.
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase 4, Open-Label, Multicenter, Efficacy, Safety, Pharmacokinetics and Pharmacodynamics Trial of Intravenous KRYSTEXXA® (Pegloticase) Administered Every 4 Weeks With Co-Administration of Weekly Doses of Methotrexate in Patients With Uncontrolled Refractory Gout (FORWARD Open-Label [OL] Trial)
• Actual Study Start Date: January 26, 2021
• Estimated Primary Completion Date: August 31, 2023
• Estimated Study Completion Date: October 2, 2023

Arms and Interventions

Arm	Intervention/treatment
Experimental: Pegloticase 16mg cohort; 16 mg IV dose of pegloticase q4 weeks with 15 mg methotrexate (MTX) weekly	Biological: Pegloticase and Methotrexate (MTX); 16 mg IV dose of pegloticase q4 weeks co-administered with 15 mg oral dose methotrexate weekly
Experimental: Pegloticase 24/32mg cohort; 24 to 32 mg IV dose of pegloticase q4 weeks with 15 mg MTX weekly	Biological: Pegloticase and Methotrexate (MTX); Potential higher IV dose of pegloticase (between 24-32 mg) q4 weeks co-administered with 15 mg oral dose methotrexate weekly and/or potential reduction of infusion duration

Outcome Measures

Primary Outcome Measures :

1. Participants achieving and maintaining serum uric acid (sUA) concentration <6 mg/dL for at least 80% of the time [ Time Frame: Month 6 ]
   Proportion of responders at Month 6 (Weeks 20, 21, 22, 23 and 24), defined as subjects achieving and maintaining sUA <6 mg/dL for at least 80% of the time during Month 6
2. Total duration of sUA concentration <6 mg/dL [ Time Frame: Week 24 ]
   Time to first sUA ≥6 mg/dL after first achieving sUA <6 mg/dL, from the first pegloticase infusion until Week 24

Secondary Outcome Measures :

1. Pharmacokinetic parameters (e.g., AUC, Cmax and Ctrough) [ Time Frame: Baseline to 24 months ]
2. Proportion of subjects with pre-infusion sUA <6 mg/dL at each scheduled visit [ Time Frame: Baseline to 25 months ]
3. Area under the sUA concentration vs time curve from Day 1 to Week 24 and Day 1 to Week 48 [ Time Frame: Day 1 to Week 24 and Day 1 to Week 48 ]
4. Proportion of the subjects sustained sUA< 6 mg/dL from Day 1 to Week 24 and Day 1 to Week 48 [ Time Frame: Day 1 to Week 24 and Day 1 to Week 48 ]
5. Proportion of subjects with anti-uricase antibodies and the proportion of subjects with anti-poly (ethylene glycol) antibodies and their titers at each scheduled visit [ Time Frame: Baseline to 24 months ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 80 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Willing and able to give informed consent.
2. Willing and able to comply with the prescribed treatment protocol and evaluations for the duration of the trial.
3. Adult men or women ≥18 and <80 years of age.

4. Uncontrolled gout, defined as meeting the following criteria:

   • Hyperuricemia during the screening period defined as sUA ≥6 mg/dL, and;
   • Failure to maintain normalization of sUA with xanthine oxidase inhibitors at the maximum medically appropriate dose, or with a contraindication to xanthine oxidase inhibitor therapy based on medical record review or subject interview, and;

   • Symptoms of gout including at least 1 of the following:

     • Presence of at least one tophus
     • Recurrent flares defined as 2 or more flares in the past 12 months prior to screening
     • Presence of chronic gouty arthritis as evidenced by either clinical signs consistent with chronic synovitis on clinical examination or the presence of typical gouty erosion(s) on hand and/or foot X-rays
5. Willing to discontinue any oral urate lowering therapy for at least 7 days prior to MTX dosing at Week -4 and remain off while receiving pegloticase treatments.
6. Women of childbearing potential (including those with an onset of menopause <2 years prior to screening, non-therapy-induced amenorrhea for <12 months prior to screening, or not surgically sterile [absence of ovaries and/or uterus]) must have negative serum/urine pregnancy tests during Screening and Week -4; subjects must agree to use 2 reliable forms of contraception during the trial, one of which is recommended to be hormonal, such as an oral contraceptive. Hormonal contraception must be started ≥1 full cycle prior to Week -4 (start of MTX) and continue for 4 weeks/30 days after the last dose of pegloticase, or at least one ovulatory cycle after the last dose of MTX (whichever is the longest duration after the last dose of pegloticase or MTX). Highly effective contraceptive methods (with a failure rate <1% per year), when used consistently and correctly, include implants, injectables, combined oral contraceptives, some intrauterine devices, sexual abstinence, or vasectomized partner.
7. Men who are not vasectomized must agree to use appropriate contraception so as to not impregnate a female partner of reproductive potential during the trial, beginning with the initiation of MTX at Week -4 and continuing and for at least 3 months after the last dose of MTX.
8. Able to tolerate MTX 15 mg orally for 4 weeks (Week -4 through Day 1) prior to enrollment.

Exclusion Criteria:

1. Weight >160 kg (352 pounds) at Screening.
2. Any serious acute bacterial infection, unless treated and completely resolved with antibiotics at least 2 weeks prior to the Day 1 Visit.
3. Severe chronic or recurrent bacterial infections, such as recurrent pneumonia or chronic bronchiectasis.
4. Current or chronic treatment with systemic immunosuppressive agents such as MTX, azathioprine, or mycophenolate mofetil; prednisone ≥10 mg/day or equivalent dose of other corticosteroid on a chronic basis (3 months or longer) would also meet exclusion criteria.
5. History of any transplant surgery requiring maintenance immunosuppressive therapy.
6. Known history of hepatitis B virus surface antigen positivity or hepatitis B DNA positivity.
7. Known history of hepatitis C virus RNA positivity, unless treated and viral load is negative.
8. Known history of Human Immunodeficiency Virus (HIV) positivity.
9. Glucose-6-phosphate dehydrogenase deficiency (tested at the Screening Visit centrally or locally).
10. Chronic renal impairment defined as estimated glomerular filtration rate (eGFR) <40 mL/min/1.73 m^2 or currently on dialysis.
11. Non-compensated congestive heart failure or hospitalization for congestive heart failure within 3 months of the Screening Visit, uncontrolled arrhythmia, treatment for acute coronary syndrome (myocardial infarction or unstable angina), or uncontrolled blood pressure (>160/100 mmHg) prior to enrollment at Day 1.
12. Pregnant, planning to become pregnant, breastfeeding, planning to impregnate female partner, or not on an effective form of birth control, as determined by the Investigator.
13. Prior treatment with pegloticase, another recombinant uricase (rasburicase), or concomitant therapy with a polyethylene glycol-conjugated drug.
14. Known allergy to pegylated products or history of anaphylactic reaction to a recombinant protein or porcine product.
15. Contraindication to MTX treatment or MTX treatment considered inappropriate.
16. Known intolerance to MTX.
17. Receipt of an investigational drug within 4 weeks or 5 half-lives, whichever is longer, prior to MTX administration at Week -4 or plans to take an investigational drug during the trial.
18. Liver transaminase levels (AST or ALT) > 1.25 X upper limit of normal (ULN) or albumin < the lower limit of normal (LLN) at the Screening Visit.
19. Chronic liver disease.
20. White blood cell count <4000/µl, hematocrit <32 percent, or platelet count <75,000/µl.
21. Currently receiving systemic or radiologic treatment for ongoing cancer, excluding non-melanoma skin cancer.
22. History of malignancy within 5 years other than non-melanoma skin cancer or in situ carcinoma of cervix.
23. Diagnosis of osteomyelitis.
24. Known history of hypoxanthine-guanine phosphoribosyl-transferase deficiency, such as Lesch-Nyhan and Kelley-Seegmiller syndrome.
25. Unsuitable candidate for the trial, based on the opinion of the Investigator (e.g., cognitive impairment), such that participation might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements or complete the trial.
26. Alcohol use in excess of 3 alcoholic beverages per week.
27. A known intolerance to all protocol standard gout flare prophylaxis regimens (i.e., subject must be able to tolerate at least one: colchicine and/or non-steroidal anti-inflammatory drugs and/or low dose prednisone ≤10 mg/day).
28. Current pulmonary fibrosis, bronchiectasis or interstitial pneumonitis. If deemed necessary by the Investigator, a chest X-ray may be performed during Screening.

Contacts and Locations

Contacts

Contact: Horizon Therapeutics; 1-866-479-6742; clinicaltrials@horizontherapeutics.com

Locations

United States, Alaska

Orthopedic Physicians Alaska; Recruiting

Anchorage, Alaska, United States, 99508

Contact: Anna Campione 907-341-5220 acampione@opaak.com

Principal Investigator: John Botson, MD

United States, Arizona

Arizona Arthritis & Rheumatology Research, PLLC; Recruiting

Glendale, Arizona, United States, 85306

Contact: Rebecca Martinez 480-626-6650 Tesser.research@azarthritis.com

Principal Investigator: John Tesser, MD

United States, California

East Bay Rheumatology Medical Group, Inc.; Recruiting

San Leandro, California, United States, 94578

Contact: Jacquelene Catap 510-357-1040 jcatap@ebrri.com

Principal Investigator: Suneet Grewal, MD

United States, Florida

ProHealth Research Center; Recruiting

Doral, Florida, United States, 33166

Contact: Johanna Garcia 305-960-7934 jgarcia@prohealthresearchcenter.com

Principal Investigator: David Jativa, MD

Napa Research Center; Recruiting

Pompano Beach, Florida, United States, 33064

Contact: Magda Hernandez 954-773-9890 mhernandez@napatrials.com

Principal Investigator: Naval Parikh, MD

GCP Clinical Research; Not yet recruiting

Tampa, Florida, United States, 33064

Contact: Marlene Klingeman 321-315-0780 marlenek@gcpclinicalresearch.com

Principal Investigator: Karon Locicero, MD

United States, Maryland

The Center for Rheumatology and Bone Research; Recruiting

Wheaton, Maryland, United States, 20902

Contact: Megan Lormore 301-942-6610 mlormore@arapc.com

Principal Investigator: Jeffrey Potter, MD

United States, North Carolina

Shelby Clinical Research, LLC; Not yet recruiting

Shelby, North Carolina, United States, 28150

Contact: Pamela Seagle 980-552-9230 pseagle@shelbyclinicalresearch.com

Principal Investigator: Christopher Martin, MD

United States, Pennsylvania

Altoona Center for Clinical Research; Recruiting

Duncansville, Pennsylvania, United States, 16635

Contact: Lisa Claycomb, CRCP 814-296-6101 altoonaresearch@gmail.com

Principal Investigator: Alan Kivitz, MD

United States, Texas

Biopharma Informatic, LLC; Recruiting

Houston, Texas, United States, 77043

Contact: Hassan Khan 281-944-3610 Abigail@biopharmainfo.net

Principal Investigator: Abigail Neiman, MD

United States, Washington

Arthritis Clinic: Western Washington Medical Group; Recruiting

Bothell, Washington, United States, 98021

Contact: Kathryn Lockhart 425-248-2635 klockhart@wwmedgroup.com

Principal Investigator: Jeff Peterson, MD

Arthritis Northwest PLLC; Recruiting

Spokane, Washington, United States, 99204

Contact: Terri Cone, BSN 509-838-6500 ext 310 tcone@arthritisnw.com

Principal Investigator: Howard Kenney, MD

Sponsors and Collaborators

Horizon Therapeutics Ireland DAC

Investigators

• Study Director: Supra Verma, MD; Horizon Therapeutics

More Information

• Responsible Party: Horizon Therapeutics Ireland DAC
• ClinicalTrials.gov Identifier: NCT04762498
• Other Study ID Numbers: HZNP-KRY-408
• First Posted: February 21, 2021
• Last Update Posted: December 13, 2022
• Last Verified: December 2022

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Undecided

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Horizon Pharma Ireland, Ltd., Dublin Ireland ( Horizon Therapeutics Ireland DAC ):

Gout; KRYSTEXXA; Pegloticase; Methotrexate; Uncontrolled gout

Additional relevant MeSH terms:

Gout; Arthritis; Joint Diseases; Musculoskeletal Diseases; Crystal Arthropathies; Rheumatic Diseases; Purine-Pyrimidine Metabolism, Inborn Errors; Metabolism, Inborn Errors; Genetic Diseases, Inborn; Metabolic Diseases; Methotrexate; Abortifacient Agents, Nonsteroidal; Abortifacient Agents; Reproductive Control Agents; Physiological Effects of Drugs; Antimetabolites, Antineoplastic; Antimetabolites; Molecular Mechanisms of Pharmacological Action; Antineoplastic Agents; Dermatologic Agents; Enzyme Inhibitors; Folic Acid Antagonists; Immunosuppressive Agents; Immunologic Factors; Antirheumatic Agents; Nucleic Acid Synthesis Inhibitors